PDCD1 and non-small cell lung carcinoma: A pilot study in a small French-Canadian cohort (n = 205) suggested that benzodiazepine (BZD) use correlates with reduced progression-free survival in NSCLC patients receiving PD-1/PD-L1 blockade.